Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Operating Expenses (2016 - 2025)

Heron Therapeutics' Operating Expenses history spans 14 years, with the latest figure at $29.4 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 11.57% year-over-year to $29.4 million; the TTM value through Dec 2025 reached $116.1 million, down 0.91%, while the annual FY2025 figure was $116.1 million, 0.91% down from the prior year.
  • Operating Expenses reached $29.4 million in Q4 2025 per HRTX's latest filing, down from $30.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $86.4 million in Q1 2022 to a low of $26.4 million in Q4 2024.
  • Average Operating Expenses over 5 years is $48.2 million, with a median of $38.0 million recorded in 2022.
  • The largest YoY upside for Operating Expenses was 19.75% in 2022 against a maximum downside of 49.11% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $74.2 million in 2021, then crashed by 49.11% to $37.8 million in 2022, then fell by 8.44% to $34.6 million in 2023, then fell by 23.69% to $26.4 million in 2024, then grew by 11.57% to $29.4 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Operating Expenses are $29.4 million (Q4 2025), $30.4 million (Q3 2025), and $29.0 million (Q2 2025).